Investigating the Immune System in chrONIC Kidney Disease. (SONIC)
Investigating the Immune System in chrONIC Kidney Disease - the SONIC Study.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
Compared to the general population, people with CKD are known to get more infections and are more likely to have complications from them. Protective measures such as vaccinations for common infections are not as effective in patients with CKD as they are in people with healthy kidneys. The reasons why this happens are not very clear. It is known that with increasing age, the body's immune defences are weakened, but it is not yet clear how different this is in older people with CKD compared to older people with healthy kidneys. Understanding how CKD affects the body's immune defence to new infections is vital in helping to prevent severe consequences from infection and make vaccination more effective for this group of people. This project aims to look at the function of immune cells in CKD patients and people with normal kidney function, together with their responses to clinically recommended vaccinations, including Pneumococcus (common pneumonia organism) and the influenza virus (the flu).
Study participants are invited to receive the clinically recommended seasonal influenza and pneumococcal polysaccharide vaccines during the seasonal influenza vaccination season (September - December), mirroring routine care they would receive in the community. Information on age, gender and pre-existing health problems, together with blood and urine samples will be collected from CKD patients for comparison with healthy volunteers at the following timepoints: day of vaccination, day 7 and 28 and 6 months after vaccination.
Тип исследования
Регистрация (Действительный)
Контакты и местонахождение
Места учебы
-
-
West Midlands
-
Birmingham, West Midlands, Соединенное Королевство
- University Hospitals Birmingham NHS Foundation Trust
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
CKD patients - individuals attending local tertiary care nephrology clinics.
Healthy control subjects - individuals accompanying CKD patients to nephrology clinics or individuals invited to participate from Birmingham 1000 Elders Cohort.
Описание
Inclusion Criteria:
- any gender
- aged 65 and over
Exclusion Criteria:
- Subjects who have had Pneumovax within last 5 years
- Subjects who have had current season's influenza vaccine
- CKD patients: eGFR less than 15ml/min or greater than 60ml/min, immune mediated cause of kidney disease.
- Healthy control subjects: known kidney disease, eGFR less than 60ml/min
- Subjects with comorbidities that are associated with an immunosuppressed state including, but not limited to, the following: Malignancy diagnosed within last 5 years except non-melanoma skin cancer; Solid organ (including kidney) or bone marrow transplant recipients; Blood borne viral infections: HIV, hepatitis B and C; Autoimmune disease e.g. vasculitis, rheumatoid arthritis; Previous splenectomy or asplenia from any other cause.
- Subjects currently taking any of the following immunosuppressive medications: Systemic corticosteroids e.g. prednisolone/dexamethasone; Chemotherapy agents e.g. cyclophosphamide, methotrexate, azathioprine; Biological therapies e.g. rituximab, infliximab, etanercept - including any administration within preceding 12 months.
- Subjects who have previously had a serious reaction to influenza vaccination, including anaphylaxis and Guillain-Barre Syndrome within 6 weeks of previous influenza vaccination
- Subjects who have a severe egg allergy (contraindication to influenza vaccination)
- Subjects who have previously had a serious reaction to the whole or any components of pneumococcal vaccination
- Subjects who have an active infection and/or are febrile on assessment
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: Кейс-контроль
- Временные перспективы: Перспективный
Когорты и вмешательства
Группа / когорта |
Вмешательство/лечение |
|---|---|
|
Chronic Kidney Disease (CKD) patients
Any gender, aged 65 years and over.
Chronic kidney disease with eGFR between 15 and 60 ml/min.
No immunological cause of kidney disease.
Not immunosuppressed.
To receive both seasonal influenza and pneumococcal polysaccharide vaccines as part of recommended clinical care.
|
Vaccination
|
|
Healthy Control subjects
Any gender, aged 65 years and over.
No known renal disease and eGFR 60ml/min or greater.
Not immunosuppressed.
To receive both seasonal influenza and pneumococcal polysaccharide vaccines as part of recommended clinical care.
|
Vaccination
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Proportion of participants achieving adequate humoral response to either vaccine
Временное ограничение: 28 days
|
as assessed by vaccine-specific serum IgG levels
|
28 days
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Proportion of participants who maintain protective antibody titres to either vaccine at 6 months after vaccination
Временное ограничение: 6 months
|
as assessed by vaccine-specific serum IgG levels
|
6 months
|
|
Relationship between eGFR and immune cell subsets following vaccination
Временное ограничение: 6 months
|
investigatory outcome - will be assessed using flow cytometric techniques and established biochemical laboratory eGFR testing
|
6 months
|
|
Relationship between eGFR and reported infection rates
Временное ограничение: 6 months
|
as assessed using established biochemical laboratory eGFR testing and participant reported infection-related events
|
6 months
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Lorraine Harper, University of Birmingham
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Ожидаемый)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Оценивать)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- RG_14-216
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .